NASDAQ:UTHR United Therapeutics Q3 2026 Earnings Date & Estimates $532.78 -12.22 (-2.24%) Closing price 10/8/2026 04:00 PM EasternExtended Trading$532.90 +0.12 (+0.02%) As of 10/8/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. United Therapeutics is expected to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for October 28, 2026 at 9:00 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 4, 2026TimeBefore Market OpensConference Call DateOctober 28, 2026Conference Call9:00 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from United Therapeutics in Q3 2026United Therapeutics is expected to post earnings of $6.40 per share on revenue of $785.95 million. In the same quarter a year earlier United Therapeutics reported $7.16 per share on revenue of $799.50 million. United Therapeutics last reported on August 5, 2026, posting $7.27 per share and beating the $6.86 consensus estimate. United Therapeutics has beaten the consensus EPS estimate in 6 of its last 8 quarters.Consensus EstimatesConsensus EPS$6.40Expected Revenue$785.95 millionPrior-Year EPS$7.16Prior-Year Revenue$799.50 millionExpected EPS Growth-10.6%Expected Revenue Growth-1.7%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS$7.27 (Beat by +$0.41)Last Quarter Revenue$783.30 millionEPS Beat Rate6 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report United Therapeutics Q3 2026 Earnings FAQ When does United Therapeutics report Q3 2026 earnings? United Therapeutics (NASDAQ:UTHR) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is United Therapeutics' Q3 2026 earnings call? United Therapeutics' Q3 2026 earnings conference call is scheduled for Wednesday, October 28, 2026 at 9:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for United Therapeutics? Analysts expect United Therapeutics to post earnings of $6.40 per share for Q3 2026. How much revenue is United Therapeutics expected to report? The consensus revenue estimate for United Therapeutics is $785.95 million for Q3 2026. United Therapeutics Earnings HeadlinesRBC Capital Remains a Buy on United Therapeutics (UTHR)October 8 at 11:08 AM | theglobeandmail.com3 Reasons to Avoid UTHR and 1 Stock to Buy InsteadOctober 7 at 12:52 PM | finance.yahoo.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. | Banyan Hill Publishing (Ad)Connect Biopharma (NASDAQ:CNTB) vs. United Therapeutics (NASDAQ:UTHR) Financial AnalysisOctober 4, 2026 | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) Stock Falls 4.1% After Insider SellingOctober 4, 2026 | americanbankingnews.comTop Medical Stocks To Consider - September 30thOctober 3, 2026 | americanbankingnews.comSee More United Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like United Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on United Therapeutics and other key companies, straight to your email. Email Address About United TherapeuticsUnited Therapeutics (NASDAQ:UTHR) is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment. United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets. Its medicines are used to help improve exercise capacity and delay disease progression in patients with PAH, a chronic condition involving high blood pressure in the arteries of the lungs. In addition to its pharmaceutical business, the company is pursuing technologies intended to address the shortage of transplantable organs. Its research activities include the development of genetically engineered organs from pigs, lung regeneration and preservation, and three-dimensional bioprinting. United Therapeutics was founded in 1996 by Martine Rothblatt, who serves as chairperson and chief executive officer.View United Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Levi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueSkydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand Explodes Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
